Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-1400/INO-1401 +/- INO-9012 in high-risk solid tumors
NCT02960594Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Dec 2014
- Primary completion
- Nov 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-1400 and INO-1401 in breast cancer, lung cancer, pancreatic cancer (PC) and 6 more (10 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Adverse events graded in accordance with CTCAE up to 2 years, Injection site reactions up to 14 weeks and 1 more. Started Dec 2014; status: completed.
02
Drugs
INO-1400INO-1401
03
Conditions
breast cancerlung cancerpancreatic cancer (PC)head and neck cancer (HNC)ovarian cancer
Beyond the preview
Go deeper on NCT02960594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960594.